Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia.

Authors:
Nachmias B; Krichevsky S; Filon D; Even-Or E; Gatt ME and 5 more

Journal:
Acta Haematol

Publication Year: 2022

DOI:
10.1159/000526353

PMCID:
PMC9808772

PMID:
35933982

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Acta Haematol

Abbreviation: Acta Haematol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Utility of Galactomannan Screening for Early Detection of Invasive Aspergillosis in High-Risk Hemat…
Sabbah R; Korem M; Shaulov A and 2 more (2023) - Transparency Score: 3/6
Association between Thrombin Generation and Clinical Characteristics in COVID-19 Patients.
Cohen O; Landau N; Avisahai E and 12 more (2022) - Transparency Score: 3/6
Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractor…
Wang ZY; Gao WH; Zhao HJ and 12 more (2022) - Transparency Score: 3/6
Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pan…
Langerbeins P; Eichhorst B. (2021) - Transparency Score: 2/6
Romiplostim for Primary Immune Thrombocytopenia in Routine Clinical Practice: Results from a Multic…
Reiser M; Josten KM; Dietzfelbinger H and 4 more (2021) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of Interest Statement No conflicts of interest to disclose."

Evidence found in paper:

"No funding to report."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025